Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494

Next Previous
X
Search
Trial Profile

A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary) ; Tofacitinib
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie

    • Most Recent Events

    • 25 Aug 2019 Results from two phase 1 studies assessing upadacitinib IR dosage in healthy subjects and subjects with rheumatoid arthritis, published in the Journal of Clinical Pharmacology.
    • 03 Apr 2019 Upadacitinib pharmacokinetic data from 12 studies spanning phase I , II and III clinical trials utilizing IR and ER formulations were combined and analyzed simultaneously using non-linear mixed-effects modeling; results published in the Clinical Pharmacokinetics
    • 26 Oct 2017 Results (n=573) assessing population pharmacokinetics of Upadacitinib in healthy subjects and subjects with rheumatoid arthritis from NCT01741493, NCT02066389, and NCT01960855 studies, published in the Clinical Pharmacokinetics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top